ABILIFY Now Applicable to Maintenance Treatment of Bipolar Disorder: FDA Approves New Indication

Main Category: Bipolar
Article Date: 13 Mar 2005 - 12:00 PDT

Current ratings for:
'ABILIFY Now Applicable to Maintenance Treatment of Bipolar Disorder: FDA Approves New Indication'

Patient / Public:not yet rated

Healthcare Prof:not yet rated


Tokyo (JCNN) - Bristrol-Myers Squibb (BMS) and Otsuka Pharmaceutical have jointly announced that the US Food and Drug Administration (FDA) approved an additional indication for ABILIFY (aripiprazole) Tablets and Oral Solution, atypical antipsychotics, as of March 1.

With this approval, ABILIFY is now applicable to the maintenance treatment, namely preventing relapses, of bipolar I disorder. Since its initial approval in 2002, over 3.7 million prescriptions have been written in the US.

In Japan, ABILIFY , for which a new drug application was filed in March 2003, is currently under examination.

View Otsuka Pharmaceutical Co., Ltd. company profile here

Copyright © 2001-2004 JCNN. All rights reserved. A division of Japan Corporate News Network KK.

View drug information on Abilify.


Article adapted by Medical News Today from original press release.
Visit our bipolar section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Trish Malden. "ABILIFY Now Applicable to Maintenance Treatment of Bipolar Disorder: FDA Approves New Indication." Medical News Today. MediLexicon, Intl., 13 Mar. 2005. Web.
25 May. 2012. <http://www.medicalnewstoday.com/releases/21156.php>
APA
Trish Malden. (2005, March 13). "ABILIFY Now Applicable to Maintenance Treatment of Bipolar Disorder: FDA Approves New Indication." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/21156.php.

Please note: If no author information is provided, the source is cited instead.


Add Your Opinion On This Article

'ABILIFY Now Applicable to Maintenance Treatment of Bipolar Disorder: FDA Approves New Indication'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Your Name:*
E-mail Address:*
Your Opinion Title:*
Opinion:*
This is to help prevent SPAM submissions. Please enter the words exactly as they appear, including capital letters and punctuation.*

* Fields marked with a * need to be filled in before you hit the submit button.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.


Bipolar

Most Popular Articles



Follow Our Bipolar News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Bipolar Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »